Finance

Lists
Why is TNYA down 7,87%?
Dive Deeper
TNYA:NASDAQ
Tenaya Therapeutics Inc
USD 0,52
-7,87%
(-0,044) 1D
USD 0,53
+0,79% (+0,0041)
After hours
Closed: 13 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNYA...
Open
USD 0,57
High
USD 0,57
Low
USD 0,52
Mkt. cap
115,90 m
Avg. vol.
2,69 m
Volume
2,56 m
52-wk high
USD 2,07
52-wk low
USD 0,52
EPS
-USD 0,53
Beta
2,87
Shares outstanding
224,23 m
No. of employees
70
Open
USD 0,57
High
USD 0,57
Low
USD 0,52
Mkt. cap
115,90 m
Avg. vol.
2,69 m
Volume
2,56 m
52-wk high
USD 2,07
52-wk low
USD 0,52
EPS
-USD 0,53
Beta
2,87
Shares outstanding
224,23 m
No. of employees
70
News stories
From web sources and news partners
About Tenaya Therapeutics Inc
CEO-
Employees70
Founded2016
HeadquartersSouth San Francisco, Kalifornië, Verenigde State van Amerika
Sector-
Websitetenayatherapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to TNYA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for TNYA in the last 3 months.
Highest
Current USD 0,52
USD 40,00 (+7 577,54%)
Average
USD 13,00 (+2 395,20%)
Lowest
USD 3,00 (+475,82%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
USD 3,00
+475,8%
10/05/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
USD 5,00
+859,7%
08/06/2026
Cory Jubinville, PhD
LifeSci Capital
Buy
Maintained
USD 4,00
+667,8%
08/06/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
USD 40,00
+7 577,5%
08/06/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/06/2026
Andy Hsieh
William Blair
Buy
Maintained
-
-
07/29/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
USD 2,00
+283,9%
06/03/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
USD 8,00
+1 435,5%
05/15/2026
Last report
05 Aug. 2026
Fiscal period
Q2 2026
-USD 0,09 / -USD 0,07
-35,90%miss
Revenue / Est. (USD)
1,11 m / 10,00 m
-88,90%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
225,00 k
1,11 m
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
15,36 m
14,80 m
14,84 m
16,60 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,57 m
5,98 m
5,45 m
5,41 m
Operating expense
20,94 m
20,78 m
20,29 m
22,01 m
Total operating expenses
20,94 m
20,78 m
20,29 m
22,01 m
Operating income
-20,94 m
-20,78 m
-20,06 m
-20,90 m
Other non operating income
3,00 k
25,00 k
-
-1,37 m
EBT including unusual items
-20,28 m
-20,18 m
-19,27 m
-43,39 m
EBT excluding unusual items
-20,28 m
-20,18 m
-19,27 m
-21,57 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20,28 m
-20,18 m
-19,27 m
-43,39 m
Net profit margin
-
-
-8 565,33%
-3 909,28%
Earnings per share
-0,12
-0,12
-0,09
-0,09
Interest and investment income
658,00 k
575,00 k
793,00 k
697,00 k
Interest expense
-
-
-
-
Net interest expenses
658,00 k
575,00 k
793,00 k
697,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-19,07 m
-18,95 m
-18,30 m
-19,20 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme